How should patients with nondysplastic Barrett’s esophagus (NDBE) be monitored?
How should patients with nondysplastic Barrett’s esophagus (NDBE) be monitored? Evidence-Based Answer: The answer is unclear. Esophagogastroduodenoscopy (EGD) surveillance in the 3 years before a diagnosis of esophageal adenocarcinoma (EAC) is not associated with reduced odds of death from EAC in patients with NDBE (SOR: B, case-control study). Patients with NDBE undergoing 2 EGDs in the first year and then EGD every 3 years who develop EAC present with earlier stage cancer than patients not in a surveillance program (SOR: B, retrospective cohort study).
Evidence Based Practice 18(12): 8-9